

Disclaimer

- This presentation does not intend to provide a thorough and detailed view of Herantis
 Pharma Plc ('Company'). The information provided in this presentation shall not be
 considered sufficient for making any investment decisions related to the Company. Anyone
 considering an investment in the Company shall read and consider carefully all information
 provided in the formal prospectus approved by Finland's Financial Supervisory Authority
 (Finanssivalvonta).
- This presentation may include forward-looking statements, estimates, and calculations related e.g. to the Company and its markets. Such forward-looking statements, estimates, and calculations are based on expectations and assumptions of the Company, which may be inaccurate or untrue. They also involve known and unknown risks and other factors, which might cause any estimates made by the Company to materially deviate from those actualized, including the operations, financial situation, and achievements of the Company. The Company cannot be held liable for any such deviations or for any actions taken by any party based on this presentation. Known risks related to the future of the Company and its business have been described in the formal prospectus approved by Finland's Financial Supervisory Authority (Finanssivalvonta).



Where do pharmaceuticals come from?




11/11/19

Novel drugs are based on science

- Scientific discovery on disease mechanisms; or
- Novel molecule, which may be clinically relevant

Optimize Laboratory tests Preclinical studies Clinical trials

Herantis' drug development strategy



Herantis Pharma Plc



- Herantis Pharma is a public drug development company with two highly differentiated assets for unique market opportunities:
 - → CDNF to stop progression of Parkinson's disease
 - → Lymfactin®, targeted as **first curative treatment of secondary lymphedema**
- Programs originate from scientific discoveries made by worldleading researchers, published in Nature and Science
- The company is fully funded to reach unblinding in two randomized clinical trials
- Listed in Nasdaq First North Helsinki, preparing for listing in Sweden
 - → One of Europe's most active markets for public drug development companies



Neuroprotective factor CDNF for stopping the progression of Parkinson's disease

Parkinson's disease (PD)

- Progressive neurodegenerative disease impacting 7-10 million people
- Estimated annual financial burden of PD is \$50 billion
- L-dopa, a standard-of-care, has been used since 1960's!
- Known therapies only alleviate motor symptoms; Herantis' CDNF aims stop disease progression





CDNF may change how patients live with PD

Currently in Phase 1-2 clinical study funded by European Union:
 "Leading science, greatest potential to advance clinical practice"









- > Study fully recruited: 17 patients randomized in CDNF vs. placebo groups
- ➤ Topline results expected in Q1/2020
- ➤ First-in-human study in late-stage PD patients → Primary endpoint is safety



Lymfactin® gene therapy for curing secondary lymphedema

Secondary lymphedema


- Lymphedema (LE) is chronic, progressive swelling due to accumulation of lymph
 - → Disabling and disfiguring disease
 - → No approved drugs for treatment
- Herantis' Lymfactin® is the world's first and only clinical stage gene therapy that aims to repair the lymphatic system





Lymfactin® aims at reconstituting the lymphatic system


- A single Lymfactin® injection results in local VEGF-C expression for about 2 weeks
- VEGF-C is the natural human protein that promotes the growth of lymphatic vessels
- 3. Functional lymphatic system is reconstituted
- Phase 2 study recruiting at university hospitals in Sweden and Finland
- ➤ Target schedule: Recruitment completed end of 2019, unblinding 12 months later







CDNF and Lymfactin® are in placebo-controlled studies that target significant unmet needs



^{*} Randomized, double-blind, placebo-controlled Phase 2 clinical study ** Randomized, double-blind, placebo-controlled Phase 1/2 clinical study



Dual-listing in Nasdaq First North Sweden

- Herantis announced on 11 Nov 2019:
 - →Public offering in Sweden and Denmark, and private placement: max 618,018 shares to be issued at 71 SEK (~€6.65) per share
 - → Application to Nasdaq to have Herantis' shares listed in Nasdaq First North Sweden in December 2019
- Subscription period Nov 18th Dec 1st, 2019
- See <u>herantis.com/information-memorandum/</u> for details



HERANTIS

Thank you

E-mail: pekka.simula@herantis.com

Twitter: @HerantisPharma

Blog: http://herantis.com/blog/